中性粒细胞-淋巴细胞比率的变化可预测膀胱癌手术后的早期复发

IF 1.4 4区 医学 Q4 ONCOLOGY
Rumeysa Çolak, Gökmen Umut Erdem, Caner Kapar, İlkay Gültürk, Faruk Aksu, Gülçin Şahingöz Erdal, Mesut Yılmaz, Deniz Tural
{"title":"中性粒细胞-淋巴细胞比率的变化可预测膀胱癌手术后的早期复发","authors":"Rumeysa Çolak, Gökmen Umut Erdem, Caner Kapar, İlkay Gültürk, Faruk Aksu, Gülçin Şahingöz Erdal, Mesut Yılmaz, Deniz Tural","doi":"10.1111/ajco.14065","DOIUrl":null,"url":null,"abstract":"BackgroundRecurrence develops in 50% of operated bladder cancer patients. It is important to detect recurrence in advance, and there is no prognostic reliable biomarker for bladder cancer.ObjectiveThe aim of this study is to show that changes in hematological parameters before radiological imaging can predict recurrence.MethodsWe performed a retrospective cohort study of patients undergoing radical cystectomy for urothelial carcinoma of the bladder identified using our institutional database (2010–2022). Disease‐free survival (DFS) was evaluated as relapse or death due to any cause. Kaplan‐Meier analysis was used for DFS according to the follow‐up period. DFS was calculated in two groups neutrophil‐lymphocyte ratio (NLR) &lt; 3 and NLR ≥ 3. Log‐rank test was used for comparison between groups and <jats:italic>p</jats:italic> &lt; 0.05 was considered statistically significant.ResultsIn the study, 91 patients were examined. The median age was 61.0 (34–79). 57.1% of the patients were T (1–2) and 42.9% were T (3–4). The lymph node (LN) was negative in 78% and positive in 22%. Median follow‐up time and DFS were 53.4 months and 54%, respectively. The median NLR was 2.8 (0.8–8.7). For DFS, there was a significant difference according to age, T stage, and LN status (p: 0.048, 0.019, and 0.040). There was no significant difference in the NLR in terms of DFS at the time of diagnosis (p: 0.654). In follow‐ups; While there was no difference in the NLR for DFS 12 months before recurrence (p: 0.231), there was a significant difference 6 months before the relapse and at the time of recurrence (p: 0.023 and 0.031).ConclusionThe change in the NLR before radiological recurrence in bladder cancer is significant in predicting recurrence. Prospective and multi‐center research is needed to confirm our findings.","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Change in the neutrophil‐lymphocyte ratio may predict early recurrence in operated bladder cancer\",\"authors\":\"Rumeysa Çolak, Gökmen Umut Erdem, Caner Kapar, İlkay Gültürk, Faruk Aksu, Gülçin Şahingöz Erdal, Mesut Yılmaz, Deniz Tural\",\"doi\":\"10.1111/ajco.14065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BackgroundRecurrence develops in 50% of operated bladder cancer patients. It is important to detect recurrence in advance, and there is no prognostic reliable biomarker for bladder cancer.ObjectiveThe aim of this study is to show that changes in hematological parameters before radiological imaging can predict recurrence.MethodsWe performed a retrospective cohort study of patients undergoing radical cystectomy for urothelial carcinoma of the bladder identified using our institutional database (2010–2022). Disease‐free survival (DFS) was evaluated as relapse or death due to any cause. Kaplan‐Meier analysis was used for DFS according to the follow‐up period. DFS was calculated in two groups neutrophil‐lymphocyte ratio (NLR) &lt; 3 and NLR ≥ 3. Log‐rank test was used for comparison between groups and <jats:italic>p</jats:italic> &lt; 0.05 was considered statistically significant.ResultsIn the study, 91 patients were examined. The median age was 61.0 (34–79). 57.1% of the patients were T (1–2) and 42.9% were T (3–4). The lymph node (LN) was negative in 78% and positive in 22%. Median follow‐up time and DFS were 53.4 months and 54%, respectively. The median NLR was 2.8 (0.8–8.7). For DFS, there was a significant difference according to age, T stage, and LN status (p: 0.048, 0.019, and 0.040). There was no significant difference in the NLR in terms of DFS at the time of diagnosis (p: 0.654). In follow‐ups; While there was no difference in the NLR for DFS 12 months before recurrence (p: 0.231), there was a significant difference 6 months before the relapse and at the time of recurrence (p: 0.023 and 0.031).ConclusionThe change in the NLR before radiological recurrence in bladder cancer is significant in predicting recurrence. Prospective and multi‐center research is needed to confirm our findings.\",\"PeriodicalId\":8633,\"journal\":{\"name\":\"Asia-Pacific journal of clinical oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia-Pacific journal of clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajco.14065\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.14065","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景50%的膀胱癌手术患者会出现复发。提前发现复发非常重要,而目前尚无可靠的膀胱癌预后生物标志物。本研究旨在证明放射成像前血液学参数的变化可预测复发。无病生存期(DFS)以复发或因任何原因死亡为评估标准。根据随访时间对无病生存率进行卡普兰-梅耶分析。DFS按中性粒细胞-淋巴细胞比值(NLR)< 3和NLR≥3两组进行计算。组间比较采用对数秩检验,以 p < 0.05 为差异有统计学意义。中位年龄为 61.0 岁(34-79 岁)。57.1%的患者为T(1-2)型,42.9%为T(3-4)型。78%的患者淋巴结(LN)呈阴性,22%呈阳性。中位随访时间和 DFS 分别为 53.4 个月和 54%。中位 NLR 为 2.8(0.8-8.7)。在 DFS 方面,年龄、T 期和 LN 状态有显著差异(P:0.048、0.019 和 0.040)。就诊断时的 DFS 而言,NLR 没有明显差异(P:0.654)。结论膀胱癌放射学复发前 NLR 的变化对预测复发具有重要意义。结论膀胱癌放射学复发前的 NLR 变化对预测复发有重要意义,需要进行前瞻性和多中心研究来证实我们的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Change in the neutrophil‐lymphocyte ratio may predict early recurrence in operated bladder cancer

Change in the neutrophil‐lymphocyte ratio may predict early recurrence in operated bladder cancer
BackgroundRecurrence develops in 50% of operated bladder cancer patients. It is important to detect recurrence in advance, and there is no prognostic reliable biomarker for bladder cancer.ObjectiveThe aim of this study is to show that changes in hematological parameters before radiological imaging can predict recurrence.MethodsWe performed a retrospective cohort study of patients undergoing radical cystectomy for urothelial carcinoma of the bladder identified using our institutional database (2010–2022). Disease‐free survival (DFS) was evaluated as relapse or death due to any cause. Kaplan‐Meier analysis was used for DFS according to the follow‐up period. DFS was calculated in two groups neutrophil‐lymphocyte ratio (NLR) < 3 and NLR ≥ 3. Log‐rank test was used for comparison between groups and p < 0.05 was considered statistically significant.ResultsIn the study, 91 patients were examined. The median age was 61.0 (34–79). 57.1% of the patients were T (1–2) and 42.9% were T (3–4). The lymph node (LN) was negative in 78% and positive in 22%. Median follow‐up time and DFS were 53.4 months and 54%, respectively. The median NLR was 2.8 (0.8–8.7). For DFS, there was a significant difference according to age, T stage, and LN status (p: 0.048, 0.019, and 0.040). There was no significant difference in the NLR in terms of DFS at the time of diagnosis (p: 0.654). In follow‐ups; While there was no difference in the NLR for DFS 12 months before recurrence (p: 0.231), there was a significant difference 6 months before the relapse and at the time of recurrence (p: 0.023 and 0.031).ConclusionThe change in the NLR before radiological recurrence in bladder cancer is significant in predicting recurrence. Prospective and multi‐center research is needed to confirm our findings.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
175
审稿时长
6-12 weeks
期刊介绍: Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信